Introduction
The incidence of Hodgkin lymphoma (HL) in human immuno deficiency virus (HIV)-infected individuals has been increasing across countries since the advent of combination antiretroviral therapy (cART), and HL is presently one of the most frequent non-AIDS defining malignancies (1) (2) (3) . Therefore, HIV positive HL is currently an important complication of HIV infection in the cART era.
Our previous nationwide survey in Japan demonstrated that most HIV positive HL patients are EBV-positive (EBV + ) (4) . Epstein-Barr virus (EBV) is considered to play a role in the pathogenesis of an HL subset (5, 6) ; however, the frequency of EBV association in HL is markedly different between HIV positive HL (80-100%) and HIV negative HL (20-50%) (5) (6) (7) (8) . In HIV negative cases, EBV positivity is demonstrated to have a male predominance, a high incidence of mixed cellularity classical Hodgkin lymphoma (MCCHL), and advanced clinical stages (9) . The prognostic impact of EBV positivity in HL remains controversial (9) (10) (11) (12) . It has been recently reported that HIV infection has no prognostic impact on advanced-stage HL (13) . However, to the best of our knowledge, there has been no comparative clinical study that focused on the differences in the clinical features of EBV + HL between HIV positive
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A Japanese nationwide retrospective survey and negative cases. Thus, we planned an expanded survey to compare the clinical characteristics between HIV positive HL and HIV negative HL with pathologically detectable EBV in a Japanese population.
Patients and methods
In our previous retrospective nationwide study in Japan between 1991 and 2010 from 511 institutions among all regional centers and all educational hospitals certified by the Japanese Society of Hematology (4, 14) , there were only 19 HIV positive HL patients. Among them, we found 16 evaluable EBV + HIV positive HL patients for analysis in this study. The criteria for EBV-positivity were defined by EBER in situ hybridization and/or LMP-1 immunostaining (4). In addition, data of newly obtained 123 HIV negative HL patients who visited three regional hospitals (i.e., Cancer Institute Hospital of JFCR, National Hospital Organization Nagoya Medical Center, and Tokyo Medical University) between 2001 and 2010 were used for this study. Chart reviews were performed for all identified patients (Table I) (15) . Overall survival (OS) was defined as the interval from HL diagnosis to death from any cause. Progression-free survival (PFS) was defined as the interval from HL diagnosis and the date on which disease progresses or the date on which the patient dies from any causes. Two HIV positive HL patients diagnosed by autopsy were excluded from prognostic analysis. International Prognostic Score (IPS) was evaluated according to a previous report (16) . Treatment completion was defined as completing the induction therapy without discontinuance. Dose reduction was defined as a 10% or more reduction in the optimal dose calculated according to body surface area. One HIV positive HL patient was being treated with doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) at the time of this study and was therefore excluded from the analysis of treatment completion and dose reduction. Two HIV negative HL patients without evaluable clinical response were excluded from the analysis of the response rate and treatment completion (Table I) .
Statistical analysis. Age difference according to HIV status was assessed using the Wilcoxon signed rank test. The difference in clinical parameters according to the HIV status was assessed using the chi-square test or Fisher's exact test, when appropriate. Overall survival and PFS between groups divided by the HIV status were compared using the log-rank (Mantel-Cox) test. GraphPad Prism software (version 5c for Macintosh; GraphPad Software Inc., La Jolla, CA, USA) was used for the statistical analysis, and P-values <0.05 were considered to indicate a statistically significant difference.
Results
Details of EBV-positivity. Among 19 HIV positive HL patients in the previous study, there were 16 EBV-positive patients (EBER and/or LMP-1 positive 16, negative 2, unknown 1). Among the newly obtained 123 HIV negative HL patients, there were 34 EBV-positive patients (EBER and/or LMP-1 positive 34, negative 43, unknown 5, not operated 42). Table I . All HIV positive patients, but one, had HL diagnosis in the cART era (i.e., after 1997); 14 of the 16 HIV positive patients developed HL during the HIV follow-up at 40 (median) months (range, 6-84) after HIV diagnosis, and the remaining two were initially found to have HIV infection at the time of HL diagnosis. The HIV positive HL patients were significantly younger in terms of median age than the HIV negative HL patients (45 years old vs. 60.5 years old: P=0.0158). The median CD4 + cell count (CD4 + count) at HL diagnosis was 231/µl (range, 1-567/µl) in HIV-positive cases.
Characteristics of EBV
The most common subtype of HL was MCCHL in the EBV + HIV positive group and EBV + HIV negative group (68.8% vs. 61.8%, respectively). The patient's peak age of MCCHL incidence in the EBV + HIV positive group was in their 30s, whereas that in the EBV + HIV negative group was in their 60s ( Fig. 1A and B ). Patients in their 20s were not observed in the HIV positive group; patients in the EBV + HIV negative group showed a peak incidence of nodular sclerosis classical Hodgkin lymphoma (NSCHL) in their 20s and of MCCHL in their 60s similarly to previous reports (17, 18) (Fig. 1A) . By contrast, no case of NSCHL was encountered in the EBV + HIV positive group particularly in the patients who were below their 40s ( Fig. 1B ).
There were no significant differences in the incidence of advanced stage between the HIV positive group and the HIV negative group (81.3% vs. 67.6%: P=0.258), or in the presence of B symptom (50% vs. 41.2%: P= 0.388). In contrast, significantly higher incidences of extranodal involvement (56.3% vs. 20.6%: P=0.0150) and BM involvement by itself (47.8% vs. 2.9%: P=0.000748) were observed in the EBV + HIV positive group (Table I) .
Treatment response and survival. The complete remission (CR) rate of the HIV positive HL patients was not significantly different from that of the HIV negative HL patients (84.6% vs. 96.9%: P=0.196) ( Table I ). The OS of the EBV + HIV positive HL patients, including one patient under treatment, (median observational period, 23.5 months) was not significantly different from that of the EBV + HIV negative HL patients (median observational period, 64.5 months) (5-year OS probability: 65.1% vs. 79.0%; P=0.1921) ( Fig. 2A ). There was no significant difference in the PFS between EBV + HIV positive HL and EBV + HIV negative HL (5-year PFS probability: 66.8% vs. 78.7%; P=0.2835) (Fig. 2B) .
The treatment completion rate of the advanced-stage patients treated with ABVD/ABVd was 90.0% in the HIV positive HL patients and 75.0% in the HIV negative HL patients (P=0.326) ( Table I ). The rate of the patients with ABVD/ABVd dose 
Discussion
EBV infection is associated with an increased risk of EBV-positive HL. EBV may play a role in the pathogenesis of EBV-positive HL (5, 6) , but this aspect has not yet been fully clarified. There have been comparisons between HL with EBV positive and negative patients. A recent report by Koh et al describes the impact of EBV-positivity on HL in Korea (12) .
There have also been comparisons between HIV positive HL and HIV negative HL. However, there have been no comparison data on EBV-positive HL between HIV positive and negative patients. To find out the difference, we matched the condition of EBV-positivity and made a comparison between the HIV positive and negative groups. As EBV-positive HL and EBV-negative HL act differently, it is essential to divide EBV-positive HL from EBV-negative HL to elucidate the facts about the impact of HIV infection.
The frequency of HL in HIV-infected individuals has increased two-folds in the cART era (19) . It is known that HIV positive HL patients have distinct clinicopathological features such as a high rate of EBV positivity, advanced-stage disease (20) (21) (22) , and unfavorable histological subtypes, including MCCHL and lymphocyte-depleted classical HL (4). On the other hand, MCCHL is more likely to be EBV-positive across all age groups, particularly in young adults (23) . In the current study, the peak age of the patients at EBV + HIV positive HL diagnosis was during their 30s; this age distribution was quite different from that observed in general HL showing biphasic peaks. Notably, we never found NSCHL in the patients who were below their 40s in the EBV + HIV positive HL group, whereas NSCHL was generally found in younger HL patients likely in the EBV + HIV negative HL group (Fig. 1A and B ). This dissociation of pathological subtypes in the young generation in HL regarding HIV positive HL, particularly for NSCHL, should be confirmed in other ethnic cohorts as EBV-positive lymphoma is frequently encountered in Asia.
We included two patients diagnosed by autopsy, since the data of diagnosis and stage did not affect the clinical results, including outcome (Table I) . They were excluded from prognostic analysis.
We found that EBV + HIV positive HL showed a high frequency of extranodal involvement compared with EBV + HIV negative HL, in accordance with previous studies (20) (21) (22) . In particular, BM involvement was notable (47.8%) in HIV-positive patients. Ann Arbor staging (P= 0.5012) or IPS (P= 0.7489) was not significantly different whether the condition was HIV-positive or not, and the response to therapy was comparative.
We cannot simply conclude that the comparative clinical outcome between EBV + HIV positive HL and EBV + HIV negative HL in this survey is linked to the different aged populations with different pathological subtypes. Nevertheless, even with the high frequency of BM involvement in EBV + HIV positive HL, there were no significant differences in the CR rate, OS probability, and PFS compared with EBV + HIV negative HL. The current study demonstrated that the standard chemotherapy for EBV + HIV negative HL was acceptable for EBV + HIV positive HL in the cART era, and we obtained almost even results in response to chemotherapy as well as outcome between these two groups. These results further suggest that Ann Arbor staging or IPS might be helpful for planning therapeutic strategies for HL patients, including EBV + HIV positive HL patients.
Introduction of new agents such as brentuximab vedotin for CD30 blockade or nivolumab for programmed death (PD)-1 blockade (24) for relapsed HL patients, and their combination with hematopoietic stem cell transplantation for younger patients are currently major topics. PD-1 is a regulator of the survival of virus-specific CD8 + T cells in HIV infection (25) , and it also plays a wide role in HIV pathogenesis (26) . Thus, PD-1 has emerged as an attractive potential therapeutic target. The clinical effects of humanized monoclonal antibodies for PD-1, including nivolumab, for EBV + HIV positive HL are still unknown. Therefore, we should pay more attention to the outcome of EBV + HIV positive HL when treated with new agents. As most EBV + HIV positive HL patients are younger than 60 years, and more than 60% of them show MCCHL, the therapeutic strategy for such patients is an important issue to resolve.
The limitations of this study include the retrospective nature of the analysis among different institutions and terms. Although we performed a nationwide survey in Japan, the number of patients is still small because of the low incidence of HL in Japan [5% of malignant lymphoma (27) ]. Nevertheless, there have been apparently no data available regarding EBV + HL patients with comparison based on the HIV status.
In conclusion, we found that EBV + HIV positive HL preferentially occurred in a younger population with no NSCHL, particularly in patients aged less than 40 years. In patients with the advanced stage of EBV + HIV positive HL, 80% of them did not require dose-reduction and most of them completed chemotherapy. Standard chemotherapy is effective and tolerable for EBV + HL, regardless of HIV infection.
HIV positivity may not have a negative impact on the outcome in Japanese EBV + HL. Thus, further evaluation of different ethnic cohorts is needed to provide additional information for delineating EBV + HIV positive HL in the cART era.
